<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02895568</url>
  </required_header>
  <id_info>
    <org_study_id>WWARN1603</org_study_id>
    <nct_id>NCT02895568</nct_id>
  </id_info>
  <brief_title>Prevalence Survey of Plasmodium Falciparum Antimalarial Drug Resistance Markers</brief_title>
  <official_title>Prevalence Survey of Plasmodium Falciparum Antimalarial Drug Resistance Markers in Komé, Doba, Republic of Chad</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Worldwide Antimalarial Resistance Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to measure prevalence of established and candidate molecular markers of drug
      resistant malaria at Komé, Doba, Republic of Chad.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a cross-sectional, observational study using dried blood samples collected from P.
      falciparum-infected individuals at the time of malaria diagnosis to measure the prevalence of
      known and candidate molecular markers of resistance to artemisinin and non-artemisinin ACT
      partner drugs. A maximum of 200 participants will be enrolled at each participating site per
      year. Study duration is 2 years. Therefore total participant is up to 400.

      Prospective participants will have blood collected for dried blood spot (DBS) study sample
      after providing informed consent. Individuals with confirmed P. falciparum infection will
      have DBS samples included for molecular analyses for known and candidate molecular markers of
      antimalarial drug resistance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percent prevalence of kelch13 mutants (marker of resistance to artemisinins)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent prevalence of specimens with pfmdr1 copy number &gt;1 (marker of resistance to mefloquine)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visualization and dissemination of molecular marker prevalence data to inform public health officials, researchers, policymakers and key stakeholders</measure>
    <time_frame>2 yeas</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Plasmodium Falciparum</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A dried blood spot sample for study analyses will be collected at the time of blood
      collection for malaria diagnostic testing.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study participants will be the patients presenting at study clinics with signs and symptoms
        of malaria (including but not limited to headache, body aches, fever, chills, and weakness)
        and confirmed P. falciparum infection.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants must meet all of the inclusion criteria to participate in the study.

          -  Patients (6 months - 75 years) with confirmed uncomplicated P. falciparum infection

          -  Written informed consent obtained

        Exclusion Criteria:

          -  Patients presenting signs of severe malaria will be excluded from the survey to
             prevent any delay in the management of the patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mehul Dhorda, PhD</last_name>
    <email>mehul.dhorda@wwarn.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clement Kerah-Hinzoumbe, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Study clinic</name>
      <address>
        <city>Kome</city>
        <state>Doba</state>
        <country>Chad</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehul Dhorda, PhD</last_name>
      <phone>+66 (0) 23 54 91 28</phone>
      <email>mehul.dhorda@wwarn.org</email>
    </contact>
    <contact_backup>
      <last_name>Kerah Hinzoumbe Clement, PhD</last_name>
      <phone>+ 23566282431</phone>
      <email>kerah_clement@yahoo.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Chad</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2016</study_first_submitted>
  <study_first_submitted_qc>September 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2016</study_first_posted>
  <last_update_submitted>June 7, 2017</last_update_submitted>
  <last_update_submitted_qc>June 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antimalarial drug</keyword>
  <keyword>Resistance</keyword>
  <keyword>Republic of Chard</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antimalarials</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

